NEXALIN TECHNOLOGY INC. - COMMON STOCK

2,8700

21-февраля-25 16:45:00

15 мин. задержка

Акции

-0,3700

-11,42%

Сегодняшний диапазон

2,8500 - 3,2830

ISIN

N/A

Источник

NASDAQ

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

13 июн 2024 15:00:00 Источник Nasdaq GlobeNewswire
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

04 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

03 июн 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

22 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

09 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

25 апр 2024 10:44:22 Источник Nasdaq GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders

10 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

09 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

04 апр 2024 13:00:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

02 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

28 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

14 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

13 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

06 мар 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

08 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

23 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Unveils Next-Generation HALO™ Clarity

11 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

18 дек 2023 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

25 окт 2023 08:30:00 Источник Nasdaq GlobeNewswire
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

16 окт 2023 08:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.